Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
Date:8/5/2014

UEDEXTA Important Safety InformationNUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state.

Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias.

NUEDEXTA and certain other medicines can interact, causing serious side effects. If you take certain drugs or have certain heart problems, NUEDEXTA may not be right for you.

NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation should be conducted at baseline and 3-4 hours after the first dose.

The most common adverse reactions are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence. NUEDEXTA may cause dizziness.

These are not all the risks from use of NUEDEXTA. Please refer to full Prescribing Information at www.NUEDEXTA.com.

About Avanir Pharmaceuticals, Inc.Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Avanir Pharmaceuticals To Present at Three Conferences In May
2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 The North ... at a CAGR of 7.9% from 2014 to 2019. ... ) command larger shares in the dermatology diagnostic ... to grow at the highest CAGR of 9.8% during ... devices market is driven by factors such as rising ...
(Date:4/21/2015)... This report analyzes the worldwide markets for ... Equipment for Therapeutic Apheresis, and Equipment for Donor Apheresis. ... Plasmapheresis, Plateletpheresis, and Others. The report provides separate comprehensive ... Japan , Europe ... World. Annual estimates and forecasts are provided for the ...
(Date:4/21/2015)... According to a new ... Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, ... Residual Contamination, Adventitious Agents) - Global Forecast to ... Testing Market was valued at $1,758.69 Million in ... a CAGR of 12.23% to reach $3,130.85 Million ...
Breaking Medicine Technology:North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 2North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 3World Apheresis Equipment Industry 2World Apheresis Equipment Industry 3World Apheresis Equipment Industry 4World Apheresis Equipment Industry 5World Apheresis Equipment Industry 6World Apheresis Equipment Industry 7World Apheresis Equipment Industry 8World Apheresis Equipment Industry 9World Apheresis Equipment Industry 10World Apheresis Equipment Industry 11World Apheresis Equipment Industry 12World Apheresis Equipment Industry 13World Apheresis Equipment Industry 14World Apheresis Equipment Industry 15World Apheresis Equipment Industry 16World Apheresis Equipment Industry 17World Apheresis Equipment Industry 18World Apheresis Equipment Industry 19World Apheresis Equipment Industry 20World Apheresis Equipment Industry 21Biologics Safety Testing Market Worth $3,130.85 Million by 2019 2Biologics Safety Testing Market Worth $3,130.85 Million by 2019 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 4
... Sept. 14 ThermoGenesis Corp. (Nasdaq: KOOLD ), ... and store adult stem cells, said today that revenues for ... revenues of $4.0 million for the same quarter a year ... $4.8 million. The Company recorded disposable revenues of ...
... WALTHAM, Mass., Sept. 14, 2010 Amylin Pharmaceuticals, Inc. ... (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ... research findings on BYETTA® (exenatide) injection and the investigational ... presented at the 46th Annual Meeting of the European ...
Cached Medicine Technology:ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 2ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 3ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 4ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 5ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 6ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 7BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 2BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 3BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 4BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 5BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 6BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 7
(Date:4/21/2015)... (PRWEB) April 21, 2015 The joint ... today it is opening its first freestanding emergency room ... Chandler, Arizona and will be licensed under Dignity Health ... Dignity Health and Adeptus Health joint venture. , Tim ... and Mercy Gilbert Medical Centers said the new facility ...
(Date:4/21/2015)... NJ & New York, NY (PRWEB) April 21, ... leading global provider of advanced delivery technologies and ... products, today announced the launch of ADVASEPT™ Lock, ... safe and efficient delivery of injectable medications. Easily ... combining a safe, convenient and functional container closure ...
(Date:4/21/2015)... Carinsurancehints.com has released a new blog ... impact on auto insurance prices . , ... prices. Clients should review their insurance options before deciding ... under several forms. Some of the popular policies provide ... compare online rates and find the best prices in ...
(Date:4/21/2015)... PA (PRWEB) April 21, 2015 This ... & Related Skin Types, Inc.® (FIRST) will publish a ... The campaign will run throughout the month of May ... It Matters to Someone." The positioning was chosen ... this rare skin disorder and to help support our ...
(Date:4/21/2015)... Carinsuranceshoppingsource.com has released a new blog ... insurance plans . , Comprehensive auto insurance is ... situations. The coverage limit can also be high and ... protect a car against fire damage, vandalism, theft and ... no longer difficult and it can help drivers find ...
Breaking Medicine News(10 mins):Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2Health News:Comprehensive Auto Insurance Is An Important But Complex Policy 2
... Kiadis Pharma,announced today that its lead product ATIR ... Food and Drug Administration (FDA) as a therapy ... Disease (GvHD),following allogeneic bone marrow transplantation. ATIR is ... enter clinical phase III,studies in 2008. "This ...
... to treat high blood pressure and enlargement of ... caused by post-traumatic stress disorder, Alzheimer,s disease, depression ... antipsychotic medication, appears to block the increase of ... Science University and Portland Veterans Affairs Medical Center ...
... Scientists at Cold Spring Harbor Laboratory (CSHL) have developed a ... genome that is more powerful and more economical than methods ... to be a boon to many kinds of research, including ... genes implicated in major diseases such as cancer and schizophrenia. ...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today reported financial ... the quarter ended September 30, 2007, the Company reported a ... to a net loss of,$62.7 million, or $1.23 per share, ... per share, for the prior quarter ended June 30, 2007. ...
... and 6 ... other cities, RALEIGH, N.C., ... on the impact of new CPR techniques, the,results of which support the ... the study authors in a,presentation at the AHA,s Scientific Sessions on November ...
... Concise reporting would ensure validity of patient safety findings, group ... to be used as hospital safety rating tools have been ... the guidelines could help do away with misleading safety comparisons ... reporting patient safety data on their Web sites. While this ...
Cached Medicine News:Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 2Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 3Health News:Blood pressure drug curbs brain damage from PTSD 2Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 2Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 3Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 4Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 5Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 6Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 7Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 8Health News:Raleigh in National Study, Shows Survival to Hospital Discharge After Cardiac Arrest Doubles With Improved CPR and Impedance Threshold Device 2Health News:Raleigh in National Study, Shows Survival to Hospital Discharge After Cardiac Arrest Doubles With Improved CPR and Impedance Threshold Device 3
For restriction digests, immuno-precipitations, enzyme assays, TLC spotting and others...
... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...
... tips. Each box contains 1000 tips (5 bags ... tips (4 bags of 50 tips). Also available ... per pack. Bulk Packs are sealed with a ... quick access to Gilsons Diamond Tips. Bulk Packs ...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels - Ideal for use with CastAway System...
Medicine Products: